Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
Effective January31, 2019, Supernus Pharmaceuticals,Inc. (the “Company”) and Advent Key West, LLC (the “Landlord”) entered into a Lease Agreement (the “Lease”) for approximately 136,016 square feet for the Company’s new headquarters to be located at 9715 and 9717 Key West Avenue, Rockville, Maryland (the “Premises”).
The term of the Lease commences upon Landlord tendering possession of the Premises, with a fully executed lease termination with the prior tenant, which date is estimated to be on or about February1, 2019 (the “Commencement Date”), and shall continue until April30, 2034, unless earlier terminated in accordance with the terms of the Lease (the “Lease Term”).
Fixed rent with respect to the Premises shall commence on the Commencement Date. The initial fixed rental rate is $195,523 per month for the first 12 months, which rate will automatically increase by 2% on each anniversary of the Commencement Date. In the event the Commencement date of the Lease is any date other than February1, 2019, then the Company and the Landlord will enter into an amendment of the Lease to adjust the rental rate. Under the terms of theLease, the Company is required to provide a security deposit of $195,523 and will be required to pay all utility charges for the Premises and its pro rata share of any operating expenses and real estate taxes.
The Lease is filed as Exhibit10.1 to this Current Report on Form8-K, and the above description of the Lease is a summary and is qualified in its entirety by reference to the complete text of the Lease.
Item 9.01 Financial Statements and Exhibits.
The following document is filed as an Exhibit to Item 1.01 hereof:
Exhibit10.1 — Lease Agreement Dated January31, 2019.
SUPERNUS PHARMACEUTICALS INC Exhibit
EX-10.1 2 a19-4046_1ex10d1.htm EX-10.1 Exhibit 10.1 DEED OF LEASE between ADVENT KEY WEST,…
To view the full exhibit click
About Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.